Santarus Gets As Much As $80M In OTC Zegerid Deal

Faced with a need for non-dilutive cash, Santarus Inc. found relief in Schering-Plough Corp.'s agreement to pay as much as $80 million for rights to an over-the-counter, lower-dose version of Zegerid (omeprazole) for heartburn-related indications. (BioWorld Today)